Adjuvant Tamoxifen: 5 Year Control of Dormant Disease?

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 174-

  Merimsky, O ^a   Inbar, M ^a   Kovner, F ^a   Chaitchik, S ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ADULT; BREAST CANCER; CANCER RECURRENCE; CASE REPORT; FEMALE; HUMAN; LETTER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 0029939030     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00434-3     Document Type: Letter

References (5)

1. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992, 339, 1-15, 71-85.
2. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989, 320, 479-484.
3. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but marker-positive breast cancer patients by Tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 1994, 35, 80-83.
4. Merimsky O, Inbar M, Hareuveni M, Witenberg B, Wolman Y, Chaitchik S. Serial MCA measurements in the follow-up of breast cancer patients. Eur J Cancer 1991, 27, 1440-1444.
5. Merimsky O, Hareuveni M, Inbar M, et al. Increasing serum levels of mucin-like carcinoma associated antigen and mucinous antigen H23 in clinically disease-free breast cancer patients. Diagn Oncol 1993, 3, 61-66.